Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in DXB?
Dimerix: THE INVESTMENT CASE

Dimerix: Access latest PPT from Proactive's CEO Sessions

Kathy Harrison talked pending milestone news with investors.
Dimerix: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: DXB The Big Picture
Kathy Harrison, CEO, Dimerix

Dimerix’ (ASX:DXB) chief executive officer, Kathy Harrison, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.

The company will have milestone news flow in coming months from its Phase II clinical trials for chronic kidney disease.

The company's lead clinical program, DMX 200, has been granted Orphan Drug Designation status in the U.S. for a medical condition called Focal Segmental Glomerulosclerosis (FSGS).

The innovative treatment combines two existing drugs.


ACCESS THE FULL PRESENTATION HERE



Register here to be notified of future DXB Company articles
View full DXB profile View Profile

Dimerix Timeline

Newswire
January 23 2017

Related Articles

genomics.jpg
October 05 2016
Summit has inked a deal that could potentially be worth more than half a billion dollars.
picture of blood phials
May 11 2017
“2017 is off to a strong start and …we look forward to achieving additional milestones in the second quarter."
Vaxil at the vanguard of immuno-oncology
January 07 2017
The company is developing ImMucin, which targets MUC-1, a unique cancer antigen with high specificity to malignant cells, and results in a potent stimulation effect on T and B cells.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use